199 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
5 Jun 19
Bristol-Myers Squibb Announces Post-Closing Leadership Team
8:24am
Exhibit 99.1
FOR IMMEDIATE RELEASE
Bristol-Myers Squibb Announces Post-Closing Leadership Team
Experienced leadership team and evolved structure … Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
26 Apr 23
Bristol Myers Squibb Announces Leadership Transition Plan
4:35pm
Exhibit 99.1
FOR IMMEDIATE RELEASE
Bristol Myers Squibb Announces Leadership Transition Plan
Giovanni Caforio, MD, Bristol Myers Squibb Chairman … will capitalize on our significant growth opportunities under Chris’s leadership.”
Samuels said, “I want to thank Giovanni for his tremendous contributions
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
18 Dec 09
Bristol-Myers Squibb Announces Appointment of Charles Bancroft
12:00am
on increasing our cash position to nearly $10 billion through a series of important transactions, and his leadership of continuous improvement initiatives which … , senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received his B.S. in Accounting from Drexel University
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
9 Jun 14
Elected to Board of Directors
12:00am
responsibilities as chief commercial officer, Caforio will add leadership responsibility for the company-wide functions of Enterprise Services … to the role, from his training as a physician to his strong record in key leadership positions in marketing and operations in Europe, the U.S
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
23 Jan 15
Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer Effective May 5; Lamberto Andreotti to Become Chairman
12:00am
(NEW YORK, January 20, 2015) — Bristol-Myers Squibb Company (NYSE: BMY) today announced a number of leadership changes approved by its board … ,” Andreotti said. “Through his leadership and strategic vision, Jim oversaw the successful transformation of our company. As CEO of Bristol-Myers
8-K
EX-99.1
pomyx7 48c4
8 Apr 13
Departure of Directors or Certain Officers
12:00am
DEFA14A
cqowtatpt 5ph
26 Apr 23
Additional proxy soliciting materials
4:38pm
8-K
EX-99.1
c4lq tuzvrap
8 Mar 10
Departure of Directors or Certain Officers
12:00am
425
6eejq939u 9w0ovd
19 Mar 19
Business combination disclosure
7:04am
8-K
EX-99.1
jo1vpm
8 Jan 24
Regulation FD Disclosure
10:29am
425
twt2lbneu7eq053 hm4i
6 Mar 19
Business combination disclosure
7:03am
8-K
EX-99.2
64abesrfg
22 Sep 05
Entry into a Material Definitive Agreement
12:00am
PX14A6G
87vv6
6 Apr 20
Letter to shareholders
6:02am
8-K
EX-99.1
b2m4ug1l 9h
4 Mar 11
Bristol-Myers Squibb Names Elliott Sigal, M.D., Ph.D., to
12:00am
DEFA14A
478jof0aoxa 6w9o6s
22 Apr 24
Additional proxy soliciting materials
8:16am
DEFA14A
62kiqdhrj2fek9v7li
8 Apr 13
Additional proxy soliciting materials
12:00am
8-K
EX-99.1
4ui8s261a4lg
2 Dec 05
Departure of Directors or Principal Officers
12:00am
425
xj8gs991imeaa6c5
19 Nov 09
Business combination disclosure
12:00am